Cargando…
Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy
BACKGROUND: We aimed to assess the efficacy and safety of erenumab, a fully human monoclonal antibody inhibiting the calcitonin gene-related peptide receptor (CGRPr), for the prevention of migraine in a real-life setting. MAIN BODY: We included in our observational study all patients with episodic o...
Autores principales: | Ornello, Raffaele, Casalena, Alfonsina, Frattale, Ilaria, Gabriele, Amleto, Affaitati, Giannapia, Giamberardino, Maria Adele, Assetta, Maurizio, Maddestra, Maurizio, Marzoli, Fabio, Viola, Stefano, Cerone, Davide, Marini, Carmine, Pistoia, Francesca, Sacco, Simona |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Milan
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7137484/ https://www.ncbi.nlm.nih.gov/pubmed/32264820 http://dx.doi.org/10.1186/s10194-020-01102-9 |
Ejemplares similares
-
Association between response to triptans and response to erenumab: real-life data
por: Frattale, Ilaria, et al.
Publicado: (2021) -
Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region
por: Ornello, Raffaele, et al.
Publicado: (2020) -
Cranial autonomic symptoms and response to monoclonal antibodies targeting the Calcitonin gene-related peptide pathway: A real-world study
por: De Matteis, Eleonora, et al.
Publicado: (2022) -
Gender Differences in 3-Month Outcomes of Erenumab Treatment—Study on Efficacy and Safety of Treatment With Erenumab in Men
por: Ornello, Raffaele, et al.
Publicado: (2021) -
The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal
por: Ornello, Raffaele, et al.
Publicado: (2019)